title: Advances in the proteomic discovery of novel therapeutic targets in cancer.
abstract: Proteomic approaches are continuing to make headways in cancer research by helping to elucidate complex signaling networks that underlie tumorigenesis and disease progression. This review describes recent advances made in the proteomic discovery of drug targets for therapeutic development. A variety of technical and methodological advances are overviewed with a critical assessment of challenges and potentials. A number of potential drug targets, such as baculoviral inhibitor of apoptosis protein repeat-containing protein 6, macrophage inhibitory cytokine 1, phosphoglycerate mutase 1, prohibitin 1, fascin, and pyruvate kinase isozyme 2 were identified in the proteomic analysis of drug-resistant cancer cells, drug action, and differential disease state tissues. Future directions for proteomics-based target identification and validation to be more translation efficient are also discussed.
authors.affiliation: Department of Microbiology, Biochemistry, and Immunology, Morehouse School of Medicine, Clark Atlanta University, Atlanta, GA, USA.
authors.forename: Shanchun
authors.initials: S
authors.lastname: Guo
authors.forename: Jin
authors.initials: J
authors.lastname: Zou
authors.forename: Guangdi
authors.initials: G
authors.lastname: Wang
mesh_terms: D000970:Antineoplastic Agents / Q000494:pharmacology*; D018450:Disease Progression; D015195:Drug Design; D019008:Drug Resistance, Neoplasm; D006801:Humans; D058990:Molecular Targeted Therapy; D009369:Neoplasms / Q000188:drug therapy* / Q000473:pathology; D040901:Proteomics; D015398:Signal Transduction / Q000502:physiology
chemical_list: D000970:Antineoplastic Agents
keywords: cancer; proteomics; signaling network; therapeutic target; tumorigenesis